TCG Crossover is a science-driven investment firm dedicated to advancing disruptive medicines.
Employees: 11-50
Investment Stage: Series B; Series C
Portfolio 29
| Date | Name | Website | Total Raised | Location |
| 27.08.2026 | ollin.bio | $330M | United Sta... | |
| 11.08.2026 | Vaderis Th... | vaderis.com | $152M | Switzerlan... |
| 16.06.2026 | korsana.com | - | - | |
| 16.06.2026 | damoratx.com | - | - | |
| 19.05.2026 | Accro Bios... | accropeutics.com | $62M | China |
| 01.01.2025 | candidrx.com | - | - | |
| 01.01.2025 | Adcendo | adcendo.com | $436.66M | Denmark, C... |
| 01.01.2025 | Beacon The... | beacontx.com | $170M | United Sta... |
| 01.01.2025 | ViceBio | vicebio.com | $100M | - |
| 12.06.2024 | Pheon Ther... | pheontx.com | $120M | United Kin... |
Show more
Persons 19
| Date | First Name | Last Name | Title | Location | |||
| - | Casey | - | GC and CCO | - | - | - | |
| - | Cariad | Chester | Managing P... | - | - | - | |
| - | Maryline | Malpartida | Executive ... | - | - | - | |
| - | Roger | - | - | - | - | - | |
| - | Echo | Qin | Senior Acc... | - | - | - | |
| - | Chen | Yu | Managing P... | - | - | - | |
| - | George | Feng | Associate ... | - | - | - | |
| - | Eric | Garcia | Operations... | - | - | - | |
| - | Giuliano | Marostica | Managing P... | - | - | - | |
| - | Julie | Yang | Principal | - | - | - |
Show more
News 48
Show more
Mentions in press and media 6
| Date | Title | Description |
| 11.08.2026 | Vaderis Therapeutics closes USD 152 million Series B Financing | Together, Vaderis Therapeutics' two milestones mark a significant step forward in the development of engasertib, an investigational oral allosteric AKT inhibitor. Engasertib is positioned to become the first approved therapy specifically d... |
| 19.05.2026 | Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases | Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis NEW YORK and SUZH... |
| 26.01.2026 | Corxel Raises Up to $287 Million In Series D1 To Advance Oral GLP 1 Program and Broader Cardiometabolic Pipeline | CORXEL Pharmaceuticals Limited said it has completed a Series D1 financing, raising up to $287 million to fund the development of CX11, its oral small molecule GLP-1 receptor agonist for obesity and overweight, as well as additional cardiom... |
| 14.10.2025 | Financial boost for publicly traded scale-ups | ADC Therapeutics SA, a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in ... |
| 05.01.2024 | TCG Crossover Closes $1B TCGX Fund II | TCG Crossover, a Palo Alto, CA- and NYC-based life sciences-focused investment firm with a flexible mandate to invest in both private and public companies, closed its second fund, TCGX Fund II, with $1B in capital. The fund received support... |
| 04.01.2024 | TCG Crossover (“TCGX”) Announces Oversubscribed $1B TCGX Fund II | - |